Biology and management of malignant pleural mesothelioma

European Journal of Cancer

Volumn 42, Issue 16, 2006, Pages 2706-2714

  Zucali, Paolo A ^a   Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biology; Malignant pleural mesothelioma; Management; Pemetrexed; Targeted therapy

Indexed keywords

ASBESTOS; BEVACIZUMAB; BORTEZOMIB; CISPLATIN; ERLOTINIB; FOLIC ACID ANTAGONIST; GEFITINIB; GEMCITABINE; IMATINIB; PEMETREXED; RALTITREXED; SORAFENIB; THALIDOMIDE; VATALANIB;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CELL CYCLE; CLINICAL TRIAL; DNA DAMAGE; DRUG EFFICACY; HUMAN; INCIDENCE; MESOTHELIOMA; MOLECULAR DYNAMICS; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; MESOTHELIOMA; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL NEOPLASMS;

EID: 33750057002     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.07.011     Document Type: Article

References (89)

1. Scott B., Mukherjee S., Lake R.A., and Robinson B.W.S. Malignant mesothelioma. In: Hanson H. (Ed). Textbook of lung cancer (2000), Martin Dunitz, London 273-293
2. Peto J., Decarli A., La Vecchia C., La Vecchia C., Levi F., and Negri E. The European mesothelioma epidemic. Br J Cancer 79 (1999) 666-672
3. Carbone M., Kratzke R.A., and Testa J.R. The pathogenesis of mesothelioma. Semin Oncol 29 (2002) 2-17
4. O'Brien M.E.R., Watkins D., Ryan C., et al. A randomized trial in malignant mesothelioma of early versus delayed chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 17 (2006) 270-275
5. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
6. Carbone M., Pass H.I., Rizzo P., et al. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 9 (1994) 1781-1790
7. Murthy S.S., Shen T., De Rienzo A., et al. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 20 (2000) 410-416
8. Janssen Y.M., Barchowsky A., Treadwell M., Driscoll K.E., and Mossman B.T. Asbestos induces nuclear factor kappa B (NF-kappa B) DNA-binding activity and NF-kappa B-dependent gene expression in tracheal epithelial cells. Proc Natl Acad Sci USA 92 (1995) 8458-8462
9. Luster M.I., and Simeonova P.P. Asbestos induces inflammatory cytokines in the lung through redox sensitive transcription factors. Toxicol Lett 102-103 (1998) 271-275
10. Simeonova P.P., and Luster M.I. Asbestos induction of nuclear transcription factors and interleukin 8 gene regulation. Am J Respir Cell Mol Biol 15 (1996) 787-795
11. Murthy S.S., and Testa J.R. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 180 (1999) 150-157
12. Taguchi T., Jhanwar S.C., Siegfried J.M., Keller S.M., and Testa J.R. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 53 (1993) 4349-4355
13. Flejter W.L., Li F.P., Antman K.H., and Testa J.R. Recurring loss involving chromosomes 1, 3 and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosom Cancer 1 (1989) 148-154
14. Hagemeijer A., Versnel A., Van Drunen E., et al. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet 47 (1990) 1-28
15. Fletcher A., Kazakewich H.P., Hoffer F.A., et al. Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors. N Engl J Med 324 (1991) 436-442
16. Cheng J.Q., Jhanwar S.C., Klein W.M., et al. P16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54 (1994) 5547-5551
17. Xio S., Li D., Vijg J., Sugarbaker D.J., Corson J.M., and Fletcher J.A. Co-deletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11 (1995) 511-515
18. Frizelle S.P., Grim J., Zhou J., et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 16 (1998) 3087-3095
19. Yang C.T., You L., Yeh C.C., et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 92 (2000) 636-641
20. Tolnay E., Kuhnen C., Wiethege T., Konig J.E., Voss B., and Muller K.M. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 124 (1998) 291-296
21. Dazzi H., Hasleton P.S., Thatcher N., Wilkes S., Swindell R., and Chatterjee A.K. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R): relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 61 (1990) 924-926
22. Versnel M.A., Claesson-Welsh L., Hammacher A., et al. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene 6 (1991) 2005-2011
23. Garlepp M.J., Christmas T.I., Mutsaers S.E., Manning L.S., Davis M., and Robinson B.W.S. Platelet-derived growth factor as an autocrine factor in murine malignant mesothelioma. Eur Respir Rev 3 (1993) 192-194
24. Fitzpatrick D.R., Bielefeldt-Ohmann H., Himbeck R.P., Jarnicki A.G., Marzo A.L., and Robinson B.W.S. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumour-infiltrating T-cells in malignant mesothelioma. Growth Factors 11 (1994) 29-44
25. Marzo A.L., Fitzpatrick D.R., Robinson B.W.S., and Scott B. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 57 (1997) 3200-3207
26. Masood R., Kundra A., Zhu S., et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 104 (2003) 603-610
27. Janne P.A., Taffaro M.L., Salgia R., and Johnson B.E. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 62 (2002) 5242-5247
28. Mohiuddin I., Cao X., Ozvaran M.K., Zumstein L., Chada S., and Smythe W.R. Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of Akt phosphorylation. Ann Surg Oncol 9 (2002) 310-316
29. Cacciotti P., Barbone D., Porta C., et al. SV40-dependent Akt activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 65 (2005) 5256-5262
30. Ramos-Nino M.E., Vianale G., Sabo-Atwood T., et al. Human mesothelioma cells exhibit tumor cell-specific differences in phophatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol Cancer Ther 4 (2005) 835-842
31. Kim K.U., Wilson S.M., Abayasiriwardana K.S., et al. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 33 (2005) 541-548
32. Catalano A., Rodilossi S., Rippo M.R., Caprari P., and Procopio A. Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells. J Biol Chem 279 (2004) 46706-46714
33. Galffy G., Mohammed K.A., Dowling P.A., Nasreen N., Ward M.J., and Antony V.B. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 59 (1999) 367-371
34. Edwards J.G., Swinson D.E., Jones J.L., Muller S., Waller D.A., and O'Byrne K.J. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 124 (2003) 1916-1923
35. Merritt R.E., Yamada R.E., Wasif N., Crystal R.G., and Korst R.J. Effect of inhibition of multiple steps of angiogenesis in syngeneic murine pleural mesothelioma. Ann Thorac Surg 78 (2004) 1042-1051
36. Narasimhan S.R., Yang L., Gerwin B.I., and Broaddus V.C. Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am J Physiol 275 (1998) L165-L171
37. Carbone M., Rizzo P., Grimley P.M., et al. Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med 3 (1997) 908-912
38. De Luca A., Baldi A., Esposito V., et al. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med 3 (1997) 913-916
39. Hirao T., Bueno R., Chen C.J., Gordon G.J., Heilig E., and Kelsey K.T. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 23 (2002) 1127-1130
40. Gordon G.J., Appasani K., Parcells J.P., et al. Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 23 (2002) 1017-1024
41. MacLachlan D.S. SV40 in human tumors: new documents shed light on the apparent controversy. Anticancer Res 22 (2002) 3495-3499
42. Lopez-Rios F., Illei P.B., Rusch V., and Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 364 (2004) 1157-1166
43. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Chest 108 (1995) 1122-1128
44. Curran D., Sahmoud T., Therasse P., van Meerbeeck J., Postmus P.E., and Giaccone G. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16 (1998) 145-152
45. Herndon J.E., Green M.R., Chahinian A.P., Corson J.M., Suzuki Y., and Vogelzang N.J. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113 (1998) 723-731
46. Janne P.A. Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer 5 (2003) 98-106
47. Steele J.P.C., and Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 16 (2005) 345-351
48. Berghmans T., Paesmans M., Lalami Y., et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38 (2002) 111-121
49. Van Meerbeeck J.P., Gaafar R., Manegold C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 (2005) 6881-6889
50. Favaretto A.G., Aversa S.M.L., Paccagnella A., et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 97 (2003) 2791-2797
51. Ceresoli G.L., Zucali P.A., Favaretto A.G., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24 (2006) 1443-1448
52. Manegold C., Symanowski J., Gatzemeier U., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 16 (2005) 923-927
53. Giaccone G., O'Brien M.E., Byrne M.J., Bard M., Kaukel E., and Smit B. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 38 (2002) S19-S24
54. Porta C., Zimatore M., Bonomi L., et al. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 48 (2005) 429-434
55. Maziak D.E., Gagliardi A., Haynes A.E., Mackay J.A., and Evans W.K. Cancer Care Ontario program in evidence-based care lung cancer disease site group. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 48 (2005) 157-169
56. Boutin C., Rey F., and Viallat J.R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 108 (1995) 754-758
57. Baldini E.H. External beam radiation therapy for the treatment of pleural mesothelioma. Thorac Surg Clin 14 (2004) 543-548
58. Ahamad A., Stevens C.W., Smythe W.R., et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 9 (2003) 476-484
59. Hilaris B.S., Nori D., Kwong E., Kutcher G.J., and Martini N. Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 10 (1984) 325-331
60. Rusch V., Saltz L., Venkatraman E., et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 12 (1994) 1156-1163
61. Lee J.D., Perez S., Wang H.J., Figlin R.A., and Holmes E.C. Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience. J Surg Oncol 60 (1995) 262-267
62. Rice T.W., Adelstein D.J., Kirby T.J., et al. Aggressive multimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 58 (1994) 24-29
63. Sauter E.R., Langer C., Coia L.R., Goldberg M., and Keller S.M. Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol 60 (1995) 100-105
64. Rusch V.W., and Venkatraman E.S. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68 (1999) 1799-1804
65. Sugarbaker D.J., Jaklitsch M.T., Bueno R., et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 128 (2004) 138-146
66. Baldini E.H., Recht A., Strauss G.M., et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63 (1997) 334-338
67. Maggi G., Casadio C., Cianci R., Rena O., and Ruffini E. Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 19 (2001) 346-350
68. Flores R.M. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer 49 (2005) S71-S74
69. Stahel R., and Weder W. Neoadjuvant chemotherapy in malignant pleural mesothelioma. Lung Cancer 49 (2005) S69-S70
70. Garland L., Rankin C., Scott K., et al. Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: A phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 22 (2004) [abstr 3007]
71. Govindan R., Kratzke R.A., Hernod II J.E., et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11 (2005) 2300-2304
72. Mathy A., Baas P., Dalesio O., and van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 50 (2005) 83-86
73. Cortese J.F., Gowda A.L., Wali A., Eliason J.F., Pass H.I., and Everson R.B. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 118 (2006) 521-522
74. Destro A., Ceresoli G.L., Falleni M., et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51 (2006) 207-215
75. Linder C., Linder S., Munck-Wikland E., and Strander H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 18 (1998) 2063-2068
76. Baas P., Boogerd W., Dalesio O., Haringhuizen A., Custers F., and van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48 (2005) 291-296
77. Fennell D.A., and Rudd R.M. Defective core-apoptosis signaling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 5 (2004) 354-362
78. Liu W., Bodle E., Chen J.Y., Gao M., Rosen G.D., and Broaddus V.C. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol 25 (2001) 111-118
79. Cao X.X., Mohuiddin I., Ece F., McConkey D.J., and Smythe W.R. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 25 (2001) 562-568
80. Kelly W.K., O'Connor O.A., Krug L.M., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 (2005) 3923-3931
81. Park D.J., and Lenz H.J. The role of proteasome inhibitors in solid tumors. Ann Med 36 (2000) 296-303
82. Soligo D., Servida F., Delia D., et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 113 (2001) 126-135
83. Adachi M., Zhang Y., Zhao X., et al. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin Cancer Res 10 (2004) 3853-3862
84. Zwergel T., Tahmatzopoulos A., Wullich B., Zwergel U., Stockle M., and Unteregger G. Proteasome inhibitors and their combination with antiandrogens: effects on apoptosis, cellular proliferation and viability of prostatic adenocarcinoma cell cultures. Prostate Cancer Prostatic Dis 7 (2004) 138-143
85. Oikawa T., Sasaki T., Nakamura M., et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 246 (1998) 243-248
86. Cusack Jr. J.C., Liu R., Houston M., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61 (2001) 3535-3540
87. Williams S., Pettaway C., Song R., Papandreou C., Logothetis C., and McConkey D.J. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografs. Mol Cancer Ther 2 (2003) 835-843
88. Papandreou C.N., and Logothetis C.J. Bortezomib as a potential treatment for prostate cancer. Cancer Res 64 (2004) 5036-5043
89. Sun X., Gulyas M., Hjerpe A., and Dobra K. Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett 232 (2006) 161-169